Suppr超能文献

肌张力障碍

Dystonia.

作者信息

Bressman SB, Greene PE

机构信息

Albert Einstein College of Medicine and Beth Israel Medical Center, Phillips Ambulatory Care Center, 10 Union Square East, Suite 2R, New York, NY 10003, USA.

出版信息

Curr Treat Options Neurol. 2000 May;2(3):275-285. doi: 10.1007/s11940-000-0009-y.

Abstract

Therapy for most people with dystonia is symptomatic, directed at lessening the intensity of the dystonic contractions. For a small minority of patients (eg, those with dopa-responsive dystonia, Wilson's disease, or psychogenic dystonia), specific therapy directed at one of the many causes of dystonia is available. Before initiating treatment, clinicians need to decide if a patient has a form of dystonia amenable to such therapy. The most sensitive and least costly method to diagnose DRD is a therapeutic trial of levodopa. It is, therefore, recommended to treat all those with dystonia beginning in childhood or adolescence with low-dose levodopa. For patients with generalized or segmental signs who do not respond to levodopa, other oral medications, including anticholinergics, baclofen, and benzodiazepines, may provide mild to moderate relief; these medications are often given in combinations. For those with focal dystonia, most having adult-onset disease, botulinum toxin A injections often effectively control contractions. The injections produce transient weakness and need to be repeated, generally every 3 to 5 months. There is growing renewed interest in surgical treatment. Peripheral denervating procedures may be helpful for patients with torticollis who do not obtain adequate benefit with botulinum toxin A. The central procedures of pallidotomy and pallidal stimulation are under study; their place in the treatment of the many dystonia subtypes (eg, limb vs axial, generalized vs focal, primary vs secondary) still needs to be established. There are very few studies evaluating physical and psychological therapies or the impact of diet or lifestyle in dystonia. Most clinicians consider physical therapy, including massage, a potential adjunct to medical therapy, and psychological support and stress reduction may help individuals cope with this chronic and frequently disabling condition.

摘要

大多数肌张力障碍患者的治疗是对症治疗,旨在减轻肌张力障碍性收缩的强度。对于一小部分患者(例如,患有多巴反应性肌张力障碍、威尔逊病或心理性肌张力障碍的患者),可以针对肌张力障碍的多种病因之一进行特异性治疗。在开始治疗之前,临床医生需要确定患者是否患有适合此类治疗的肌张力障碍形式。诊断多巴反应性肌张力障碍最敏感且成本最低的方法是左旋多巴治疗试验。因此,建议对所有儿童期或青春期起病的肌张力障碍患者采用小剂量左旋多巴治疗。对于对左旋多巴无反应的全身性或节段性体征患者,其他口服药物,包括抗胆碱能药物、巴氯芬和苯二氮䓬类药物,可能会提供轻度至中度缓解;这些药物通常联合使用。对于局灶性肌张力障碍患者,大多数为成人起病,肉毒杆菌毒素A注射通常能有效控制收缩。注射会产生短暂性无力,通常需要每3至5个月重复一次。人们对手术治疗的兴趣日益浓厚。周围神经切断术可能有助于对肉毒杆菌毒素A治疗效果不佳的斜颈患者。苍白球切开术和苍白球刺激等中枢手术正在研究中;它们在治疗多种肌张力障碍亚型(例如,肢体型与轴型、全身性与局灶性、原发性与继发性)中的地位仍有待确定。评估物理和心理治疗或饮食及生活方式对肌张力障碍影响的研究非常少。大多数临床医生认为物理治疗,包括按摩,是药物治疗的潜在辅助手段,心理支持和减轻压力可能有助于个体应对这种慢性且常常致残的疾病。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验